Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
332 CHF | 0.00% | -0.45% | +9.57% |
Apr. 16 | Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization | MT |
Apr. 12 | Dental Equipment Company Straumann Names New Chair | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.68 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.57% | 5B | B- | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+2.39% | 50.53B | B- | ||
+9.36% | 44.8B | B- | ||
+2.70% | 40.7B | B+ | ||
+24.51% | 32.3B | B | ||
+3.43% | 26.53B | A- | ||
+13.67% | 25.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- YPSN Stock
- Ratings Ypsomed Holding AG